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We report the case of a 73-year-old male with primary myeloid sarcoma (MS) of the prostate. He underwent remission-induction
chemotherapy followed by conventional consolidation for acute myeloid leukemia (AML). One year after initial diagnosis, he was
without evidence of AML, the longest reported period of time in the literature for a case of primary MS of the prostate. From 1985
to 2017, fifteen other cases of MS of the prostate have been reported and are reviewed here. Five cases occurred as primary MS,
without evidence of AML on bone marrow examination or prior history of hematologic disorders, and progressed to AML within
a range of three weeks to seven months. None of these cases were started on conventional chemotherapy for AML prior to
progression. Due to its rarity, primary MS of the prostate is often diagnosed incidentally, but prompt AML-targeted treatment is
crucial to delaying the progression to AML.
1. Introduction
Myeloid sarcoma (MS) is an uncommon extramedullary
tumor of immature myeloid cells, occurring in 2.4–9.1% of
patients with AML [1–3]. First described as “chloroma” in
1853 due to its green color associated with myeloperoxidase
(MPO), the phenomenon was later known as “granulocytic
sarcoma” to describe tumors of granulocytic origin [4]. More
recently, MS has been used to describe any tumor related to
acute leukemia or myelodysplastic syndromes (MDSs). MS
typically occurs concurrently with or following the onset of
systemic bone marrow leukemia, known as secondary MS.
Uncommonly, MS can precede bone marrow involvement
[5]. Primary MS is defined by MS in the absence of a history
of leukemia, MDS, or myeloproliferative neoplasm and
negative bone marrow examination. Median time to de-
velopment of AML from presentation of primary MS ranges
from five to twelve months [6].
'e most common sites of MS involvement are the soft
tissue, bone, periosteum, and lymph nodes [6]. MS of the
prostate is extremely uncommon and described in only
limited case reports. A 2016 literature review by Koppisetty
et al. found eight cases of MS of the prostate from 1997 to
2014, four of which were primary MS. Time to development
of AML in primary MS of the prostate ranged from three
weeks to four months [7]. We present a case of primary MS
of the prostate placed on standard remission-induction
chemotherapy and without evidence of AML one year later.
2. Case Presentation
A 73-year-old man presented to a urology clinic with urinary
frequency and hesitancy. His past medical history was
significant for diabetes mellitus type II, benign prostatic
hypertrophy, and chronic kidney disease stage II. He had no
prior known history of malignancy. His physical exam
showed no lymphadenopathy or palpable enlargement of the
liver or spleen. A complete blood count revealed a hemo-
globin count of 13.3 gm/dl, a white blood cell count of
5.8×109/l, and a platelet count of 245×109/l. He was initially
suspected to have benign prostatic hypertrophy and un-
derwent transurethral resection of the prostate (TURP).
However, four out of fifty-three prostate chips obtained
during TURP were found to have diffuse proliferation of
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large atypical cells positive for MPO, CD34, and CD68, with
Ki-67 of 100%. He was diagnosed with MS of the prostate
based on morphological findings.
Positron emission tomography-computed tomography
(PET-CT) was performed to screen for additional sites of
involvement but did not show any suspicious lesions.
Magnetic resonance imaging (MRI) of the pelvis with
contrast, performed two weeks after PET-CT, demon-
strated a 2.3 cm lesion in the central zone at the base of the
prostate with concern for the surrounding tissue invasion
(Figure 1). Bone marrow examination including aspiration
and biopsy which included flow cytometry performed soon
afterward did not show any evidence of AML or abnormal
myeloblasts.
'e patient was started on AML remission-induction
chemotherapy with “7 + 3” regimen, consisting of cytarabine
and idarubicin. Postinduction pelvis MRI showed decrease
in the size of the prostate mass to 1.5 cm. He subsequently
received three cycles of consolidation chemotherapy with
intermediate-dose cytarabine; serial imaging during treat-
ments showed continuous response without complete res-
olution of the prostate lesion (Figure 2). Maximum response
was achieved with the second consolidation therapy. He is
now on active surveillance with serial pelvis MRIs and labs
every three months, without evidence of systemic relapse or
pelvic progression at one year from original diagnosis.
3. Methods
A comprehensive literature review was performed through
the PubMed database from 1985 to 2017 using the keywords
myeloid sarcoma, granulocytic sarcoma, chloroma, extra-
medullary leukemic infiltration, and prostate. Articles were
screened for the abovementioned terms, specific for myeloid
lineage tumors including AML, MDS, and myeloprolifera-
tive disorders/neoplasms.
4. Results
A total of fifteen cases of myeloid sarcoma of the prostate
were found in the literature search as outlined in Tables 1
and 2. Five were diagnosed as primary MS and ten as
secondary MS. 'e age of presentation at diagnosis of MS
was between 8 and 79 years, with a median age of 66.5 years.
Of the primary MS cases, none were started on che-
motherapy for AML at the time of diagnosis due to either
initial misdiagnosis or receiving local RTas initial treatment
instead. Case 1 died shortly after undergoing TURP and
prior to systemic treatment. Cases 2 and 3 were mis-
diagnosed as lymphoma and sarcoma, respectively, and
progressed to AML within seven months. Case 2 achieved
CR and was alive 19 months after diagnosis, and case 3 died
three months after diagnosis. Both cases 4 and 5 were treated
with local RT initially and progressed to AML within four
months. After starting chemotherapy upon AML progres-
sion, both cases 4 and 5 achieved CR. Time to development
of systemic disease ranged from three weeks to seven
months. Our case represents the longest reported period
from the diagnosis of primary MS of the prostate without
development of systemic disease at one year. Ours is also the
first case started on chemotherapy for AML at the time of
discovery of primary MS of the prostate.
Secondary MS cases were split between six (cases 7–12)
with concurrent AML and four (cases 13–16) with a previous
history of AML or a clonal hematologic disorder. Patients
with concurrent systemic disease were all started on che-
motherapy upon diagnosis. 'ree (cases 7–9) died within 6
months of diagnosis, one died shortly after initiating che-
motherapy (case 10), one (case 11) had no follow-up in-
formation, and one (case 12) achieved a CR. Treatment
options differed among secondary MSs with the previous
history of systemic disease, with time from the original
disease to discovery of secondary MS ranging from six
months to nine years. Two cases (cases 13-14) underwent
only RT to the prostate bed at the time of MS of the prostate
discovery. No follow-up information was available on case
13, but case 14 experienced AML relapse just two months
after secondary MS discovery. He was started on systemic
chemotherapy and was alive five months later. Case 15
underwent both systemic chemotherapy and RT at the time
of discovery of MS but developed AML relapse with fatal
outcome six months later. Case 16 was not started on
systemic therapy at the time of MS diagnosis and developed
AML relapse four months later, at which point he was
treated with systemic chemotherapy and achieved CR. 'e
two cases (cases 13 and 16) who did not receive systemic
Figure 1: Pelvic MRI at diagnosis (axial view).
Figure 2: Pelvic MRI after treatment (axial view).
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Table 1: Primary myeloid sarcoma of the prostate.
Case Age Symptoms Hematologicaldiagnosis
Time to progression
to AML Treatment Outcomes
1 [8] 79 Urinary retention N/A N/A None Died shortly after TURP
2 [9] 67 Urinary retention AML-M2 (FABclassification) 7 months
Lymphoma-directed
chemotherapy and then
remission-induction
chemotherapy
Originally misdiagnosed as
lymphoma and received
CHOP. Started remission-
induction chemotherapy at
AML relapse and achieved
CR. Alive at 19 months after
MS diagnosis
3 [10] 32
Dysuria, weight
loss, and night
sweats
AML-M5 (FAB
classification) 3 weeks
Remission-induction
chemotherapy
Died 3 months after MS
diagnosis
4 [11] 71 Dysuria AML 4 months Chemotherapy(unspecified)
CR and further follow-up
N/A
5 [12] 71 Dysuria AML-M2 (FABclassification) 4 months
Remission-induction
chemotherapy and then
salvage chemotherapy
CR and then relapse with
salvage chemotherapy with
second CR; died 24 months
after MS diagnosis due to
brain hemorrhage
6 (present
case) 73
Frequency and
hesitancy None N/A
Remission-induction
chemotherapy followed
by consolidation
Without progression
to AML at 1 year
after MS diagnosis
AML: acute myeloid leukemia; CHOP: cyclophosphamide; doxorubicin, vincristine, and prednisone; CR: complete remission; FAB classification: French-
American-British classification; MS: myeloid sarcoma; N/A: not available; TURP: transurethral resection of the prostate.
Table 2: Secondary myeloid sarcoma of the prostate.
Case Age Symptoms Hematologicaldiagnosis
Time from
systemic
disease to MS
Treatment Outcomes
7 [13] 61 Hematuria andfrequency AML
Diagnosed
simultaneously
Doxorubicin, vincristine,
cytarabine, and prednisone
Died 5.5 months after
MS diagnosis
8 [14] 65 Urinary retentionand weight loss
AML-M4 (FAB
classification)
Diagnosed
simultaneously
Chemotherapy
(unspecified)
Died 3 weeks after
MS diagnosis
9 [15] 72 Urinary retention CMML Diagnosedsimultaneously Etoposide
CMML progressed to AML at
3 months and then died at
4 months after MS diagnosis
10 [16] N/A Urinary retention AML Diagnosedsimultaneously
Chemotherapy
(unspecified) Died; no details
11 [17] 8 Urinary retention AML-M2 (FABclassification)
Diagnosed
simultaneously High-dose cytarabine N/A
12 [18] 44 Lower urinary tractsymptoms AML
Diagnosed
simultaneously Chemotherapy and SCT
CR and further
follow-up N/A
13 [13] 72 Urinary retentionand testicular pain MDS 11 months
RT to the prostate bed
for hematuria N/A
14 [19] 65 Asymptomatic,indurated PSA
AML-M5 (FAB
classification) 13 months
RT and then salvage
chemotherapy
Initially treated with RT,
developed AML relapse
at 2 months, and underwent
salvage chemotherapy. Alive
at 5 months after MS diagnosis
15 [20] 68 Urinary retention AML-M2 (FABclassification) 9 years
RT and chemotherapy
(unspecified)
Progressed to AML at
6 months after MS
diagnosis and died
during salvage
chemotherapy shortly after
16 [6] 66 Asymptomatic,rising PSA MDS status after SCT 6 months
Induction chemotherapy
and donor lymphocyte
infusion
CR and alive at 1 year after
MS diagnosis
AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; FAB classification: French-American-British classification; MDS: myelodysplastic
syndrome; MS: myeloid sarcoma; N/A: not available; PSA: prostate-specific antigen; SCT: stem cell transplant.
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chemotherapy at the time of discovery of secondary MS had
AML relapse within four months.
5. Discussion
MS is a very uncommon manifestation of AML, reported in
2.5–9.1% of these patients [1–3]. Patients withMSmost often
have clinical evidence of concurrent AML involving the
bone marrow and/or blood. Primary MS with no evidence of
AML is rare [5]. 'e underlying molecular basis of MS is
thought to be aberrant chemokine or adhesion molecular
expression in leukemic blasts [21]. A total of 15 cases of MS
involving the prostate gland have been reported in the lit-
erature, of which 6 (40%) presented without prior or con-
current evidence of AML. Fourteen out of 15 (93.3%) cases
originally presented with lower urinary tract symptoms that
warranted further work-up, often including TURP, leading
to tissue diagnosis.
Diagnosis of MS of the prostate poses a challenging task
due to the rarity of the condition. Definitive diagnosis re-
quires a prostate tissue pathology evaluation with identifi-
cation of myeloid precursor cells. Of the sixteen cases
reviewed above, a tissue diagnosis was obtained via TURP
for nine (56.2%), prostate biopsy for five (31.2%), and
prostatectomy for two (12.5%). When possible, immuno-
histochemistry, flow cytometry, and cytogenetics studies can
aid in the diagnosis. 'e most common immunohisto-
chemical markers in MS are MPO, CD68, and lysozyme [6].
Once the diagnosis of MS is made, a bone marrow exam-
ination should be obtained to evaluate for AML.MS typically
presents as a soft tissue mass that is best suited to imaging by
PET-CT which can also be used for monitoring response to
treatment [6]. Interestingly, in our case, the PET-CTscan did
not reveal the prostatic lesion. However, MRI of the pelvis
did show the suspected prostate mass which reduced in size
with serial MRIs following initiation of treatment.
Current recommended treatment for MS with or
without evidence of systemic disease is standard therapy for
AML (remission-induction chemotherapy) [6]. Surgical
resection or RTmay be considered for local control but alone
will not lead to long-term remission of the disease. Delayed
or inadequate treatment of primaryMS almost always results
in more rapid progression to AML [22]. In a review of
different treatment outcomes for 72 cases of primary MS,
median time to development of AML is 12 months for those
receiving chemotherapy for AML versus six months for only
local radiation and three months for biopsy or surgical
resection [23]. Our review of reported cases found the time
to development of AML in primary MS of the prostate
ranging from three weeks to seven months. None of these
reported cases were started on standard therapy for AML
until they had progressed to systemic disease. Our case, at
one year, represents the longest progression-free period and
the only reported case of primary MS of the prostate started
on therapy for AML at the time of initial diagnosis of MS of
the prostate.
Data on the prognosis of MS are limited, with estimated
5-year survival rates between 20% and 30%, similar to AML
[24]. A 2006 study compared the outcomes of 16 patients
with primary MS with those of a larger cohort of AML who
underwent standard treatment [25]. When matched for
cytogenetics and age, isolated MS was associated with im-
proved event-free survival and overall survival on standard
AML therapy. 'e better outcomes, however, may be
multifactorial including the fact that these patients usually
do not die until development of AML, or that they expe-
rience less treatment-related morbidity and mortality due to
normal marrow hematopoiesis at the initiation of therapy.
MS of the prostate is rare, with 15 reported cases in the
literature from 1985 to 2017 and only 5 cases of primary
MS of the prostate. Patients typically present with lower
urinary tract symptoms, and the diagnosis is often made
incidentally. Definitive diagnosis is made by tissue diagnosis,
and a bone marrow examination is needed afterwards to
evaluate for AML. MRI of the pelvis can be useful for initial
evaluation and monitoring response to treatment if PET-CT
is nonrevealing. Primary MS of the prostate, similar to other
cases of MS, should be treated with AML-type systemic
chemotherapy promptly. Early initiation of appropriate
therapy is key in delaying progression to AML and pro-
longing survival.
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